Noncompartmental AUC Estimation for Monitoring

Why Estimate AUC From Timed Samples?

When monitoring uses an AUC target, the clinically useful quantity is the area under the concentration–time curve over the specified dosing interval. In some settings, timed concentration observations are available and a model-based estimate is not being used. The linear-up/log-down trapezoidal method provides a transparent way to estimate the area between observations and add those areas across the interval.

The calculation is only meaningful when the sample times and dosing history are interpreted correctly. In particular, samples should be assigned their actual elapsed times relative to the dose, and the interval used for comparison must match the interval to which the target refers. The earlier material on AUC Targets for Therapeutic Drug Monitoring and Sampling at Steady State establishes why those contextual checks matter; here the focus is the calculation from observed concentrations.

Segment Formulas and Their Meaning

For a rising segment, the method treats concentration as changing linearly between the two observations. The area is the width of the time interval multiplied by the average of its two endpoint concentrations:

For a declining segment with \(C_i>C_{i+1}>0\), it instead assumes an exponential decline, which is linear on a logarithmic concentration scale. This is often called a log-linear decline. The resulting area is:

The logarithmic formula requires positive concentrations. If the endpoint concentrations are equal, the formula has a zero numerator and denominator, but its limiting value is \(C_i\Delta t_i\). The linear trapezoid gives that same area directly. If a declining segment ends at zero, the logarithmic formula is undefined; a common practical convention is to use the linear trapezoid for that segment and to flag the endpoint for clinical and data-quality review.

The estimated AUC from the first observed time \(t_0\) through the last observed time \(t_m\) is:

If the samples cover the full interval from dosing time 0 to the next dose at \(\tau\), this sum estimates \(AUC_{0-\tau}\). It does not, by itself, estimate unobserved area before the first sample or after the last sample.

Why the Log Trapezoid Has This Form

For a declining segment, suppose concentration follows \(C(t)=C_i e^{-k(t-t_i)}\), where \(k>0\) is the decline rate over the segment. Since \(C_{i+1}=C_i e^{-k\Delta t_i}\), taking logarithms gives \(k=\ln(C_i/C_{i+1})/\Delta t_i\). Integrating the assumed curve from \(t_i\) to \(t_{i+1}\) yields:

The derivation shows both the strength and the limitation of the rule: it integrates the assumed exponential segment exactly, but the actual concentration curve between two sparse observations may not follow that segment.

Assumptions and Checks Before Interpreting the Estimate

The arithmetic is straightforward; deciding whether the estimate is defensible requires more care. The method assumes that each pair of observations can reasonably represent the unobserved curve between them: a straight line on rising segments and a log-linear decline on positive falling segments. It also relies on accurate concentration measurements, correct actual sample times, and a correctly identified dosing interval.

Before comparing the result with a target, check the following:

• Interval coverage: confirm that samples cover the interval required for the target. If observations begin after the dose or end before the next dose, the sum is only the area over the observed portion unless an additional justified method estimates the missing area.
• Dose and sample timing: use actual elapsed times. A delayed dose, an inaccurately recorded sample time, or a sample assigned to the wrong interval can change which segment areas are calculated.
• Curve shape: inspect for a missed peak, absorption-related curvature, multiple peaks, or abrupt changes that a single straight or log-linear segment cannot represent well. A longer gap between samples increases the opportunity for meaningful curvature to go undetected.
• Concentrations near zero: a zero or below-quantification result needs an explicit handling convention. Do not insert it into a logarithm or silently treat it as a precise measured zero.
• Clinical comparability: confirm that the target applies to the drug, patient, regimen, interval, and clinical context being assessed. A numerical match to an inapplicable target is not a valid interpretation.

At steady state, a complete dosing-interval AUC is often the intended monitoring quantity. Outside steady state, an observed interval area can still be calculated, but it may not be comparable with a target defined for steady-state exposure. The distinction is about the relevance of the comparison, not whether the segment arithmetic can be performed.

Interpreting the Estimate and Choosing an Approach

An AUC estimate is an estimated area under the observed concentration–time curve, with units of concentration multiplied by time, such as mg·h/L. Comparing it with a target should be phrased in those units and in the relevant patient context. For example, an estimate below a target range is not, by itself, proof of inadequate treatment or a complete dosing recommendation; clinical response, toxicity, regimen details, and the uncertainty of the estimate also matter.

The linear-up/log-down method is one practical approach, not the only one. A simple linear trapezoidal method uses straight-line interpolation for both rising and falling segments; it is easy to calculate but can give a different area for a curved decline. The log-down rule represents a positive declining segment as exponential, which is often more plausible for elimination-phase concentrations, but can be less appropriate when absorption or other processes cause complex curvature. Limited-sampling strategies estimate AUC from a selected set of times using a validated relationship, while model-based approaches use a pharmacokinetic model and may incorporate prior information. These alternatives have different data and model requirements; none makes poor timing or unrepresentative samples harmless.

A useful diagnostic is to compare the segment-by-segment pattern with the expected concentration profile and to look for suspiciously large contributions from long, sparsely sampled intervals. If one interval spans a likely peak or a period of rapid change, the numerical result may look precise while being sensitive to the interpolation choice. Additional samples, a validated limited-sampling strategy, or an appropriate model-based method may be preferable when the data do not support the simple interpolation assumptions.

Common Pitfalls and Limitations

• Premature rounding: rounding each segment before summing can change the reported total. Keep adequate precision through the sum, then round the final AUC.
• Using a logarithm for a rising segment: the log-down formula is intended for a positive decline. For \(C_{i+1}\geq C_i\), use the linear trapezoid.
• Using a logarithm when a concentration is zero: \(\ln(C_i/C_{i+1})\) is undefined for a zero endpoint. Apply a clearly stated alternative, such as a linear trapezoid, and review what the zero represents.
• Calling a partial area a full-interval AUC: summing from the first to last sample only covers those observed times. Do not label it \(AUC_{0-\tau}\) unless the observations cover the intended interval or missing area has been estimated by a justified method.
• Overinterpreting the number of digits: several decimal places in a calculated value do not imply comparable precision in the underlying estimate. Sampling gaps, timing uncertainty, assay measurement, and interpolation assumptions all affect reliability.
• Confusing an estimate with a dosing instruction: being above or below a target is information for interpretation, not an automatic dose change. The target’s applicability and the wider clinical picture must be considered.

The method’s main limitation is that it estimates the curve between observed points rather than observing it. More samples can reveal features that sparse data miss, but even a denser set does not remove uncertainty in measured concentrations or the need to match the estimate to an appropriate target.